M DAROLUTAMIDE (is an active metabolite) 
| DAROLUTAMIDE | ATC L02BB06
ANTINEOPLASTIC ANDROGEN RECEPTOR INHIBITOR TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | - | PPB 99.8 PERCENT HT 20 HOUR | ANDROGEN RECEPTOR (AR) | Androgen receptor inhibitor P10275 (ANDR_HUMAN) | ANSM (in French) Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |